Talk about urology

News
Webinars
Training
Daily World News
BRIDGE
Associations of Urology
By continents
International
Europa
South America
North America
Asia
Africa
Australia
By specialization
Urology
Andrology
Endo and robotic urology
Neuro-urology
Oncourology
Alphabetically
Urology Cheat Sheets
Technologies
Journals and portals
Еще
Назад к списку
Неопубликованная запись

Among treatments for nonmetastatic castration-resistant prostate cancer (nmCRPC), darolutamide may provide the best overall survival (OS) benefit, whereas abiraterone may be the most cost-effective.

Автор: 
Author's name

https://www.renalandurologynews.com/home/news/urology/prostate-cancer/nmcrpc-darolutamide-enzalutamide-apalutamide-abiraterone-efficacy-comparison/?utm_source=social&utm_medium=facebook&utm_content=ccedf268-ad4c-46b0-b928-1b521f9cba18&utm_campaign=run_daily_posts